Corvus Pharmaceuticals, Inc. (CRVS) Form 10-Q — Aug 6, 2026
Corvus Pharmaceuticals reported a Q2 2026 net loss of $18.0 million ($0.19 per share), widening from $8.0 million a year earlier, as R&D spending more than doubled to $16.0 million to fund the Phase 3 soquelitinib trial in relapsed PTCL and a new Phase 2 atopic dermatitis trial. The six-month net loss was $31.7 million versus net income of $7.2 million in the year-ago period, which had benefited from a $27.1 million warrant fair value gain. The balance sheet was dramatically strengthened: cash, cash equivalents and marketable securities totaled $215.2 million at June 30, 2026, boosted by a January 2026 follow-on offering of 9,085,778 shares at $22.15 per share that raised $189.4 million net.
Key figures
- Eps
- -$0.19 (Q2 2026); -$0.35 (six months 2026)
- Revenue
- 0
- Net Income
- -$17.96 million (Q2 2026); -$31.65 million (six months 2026)
- Total Assets
- $239.3 million
- Cash Position
- $215.2 million (cash, cash equivalents and marketable securities)
- Shares Outstanding
- 84120944
- Total liabilities
- $13.9 million
- Ga expense q2 2026
- $3.3 million
- Rd expense h1 2026
- $27.1 million
- Rd expense q2 2026
- $16.0 million
- Accumulated deficit
- $443.9 million
- Stockholders equity
- $225.3 million
- Follow on shares sold
- 9085778
- Angel pharma ownership
- 49%
- Atm capacity remaining
- $200.0 million
- Follow on price per share
- $22.15
- Angel pharma carrying value
- $15.1 million
- Phase3 ptcl enrollment target
- 150
- Prefunded warrants outstanding
- 8275913
- Jan 2026 follow on net proceeds
- $189.4 million
- Interim futility analysis timing
- anticipated early 2027
- Phase2 atopic dermatitis enrollment
- approximately 200 patients
Price after filing
Close on the filing date to close N calendar days later (from $13.92). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.